Metastatic HER2 lacrimal/salivary gland duct adenocarcinoma

BMJ Case Rep. 2023 Jun 30;16(6):e253928. doi: 10.1136/bcr-2022-253928.

Abstract

In this report, we present a case of a patient with a 30-year history of orbital asymmetry who presented with metastatic human epidermal growth factor receptor 2 (HER2) positive lacrimal/salivary gland ductal adenocarcinoma. The patient was treated with chemoradiotherapy and trastuzumab. Tumours of lacrimal gland origin are rare, and unfortunately can frequently present in late stage. There are no current guidelines on the optimal treatment of metastatic lacrimal gland tumours, in particular those with HER2 amplified malignancy. This case highlights a unique presentation of a rare disease, and the potential for targeted therapy.

Keywords: Cancer intervention; Eye; Head and neck cancer; Interventional radiology; Palliative care.

Publication types

  • Case Reports

MeSH terms

  • Adenocarcinoma* / pathology
  • Humans
  • Lacrimal Apparatus Diseases* / pathology
  • Lacrimal Apparatus* / pathology
  • Salivary Gland Neoplasms* / pathology
  • Salivary Glands / pathology
  • Trastuzumab / therapeutic use

Substances

  • Trastuzumab